<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Long-term IGF-1 maintenance in the upper-normal range has beneficial effect on low-grade inflammation marker in adults with growth hormone deficiency</dc:title><dc:creator>Klinc,	Ana	(Avtor)
	</dc:creator><dc:creator>Janež,	Andrej	(Avtor)
	</dc:creator><dc:creator>Jensterle Sever,	Mojca	(Avtor)
	</dc:creator><dc:subject>adult growth hormone deficiency</dc:subject><dc:subject>growth hormone replacement therapy</dc:subject><dc:subject>IGF-1 range</dc:subject><dc:description>The distinctive effects of maintaining the upper- (0–2) versus lower-normal (−2–0) range of IGF-1 SDS in adult growth hormone deficiency (AGHD) remain understudied. We conducted a cross-sectional study on 31 patients with AGHD receiving growth hormone replacement therapy (GHRT) with daily GH for &gt;5 years, with a 2-year mean IGF-1 SDS ranging between −2 and +2. Patients were categorized into the upper- or lower-normal range IGF-1 SDS groups according to their 2-year mean. Associations of clinical characteristics, anthropometric parameters, laboratory tests, and vascular markers of subclinical atherosclerosis with the 2-year IGF-1 SDS range and 5-year mean IGF-1 SDS were explored. Long-term maintenance of upper-normal IGF-1 SDSs was more common in men and in patients with a longer duration of GHRT. Patients with tumor-related AGHD had a lower 5-year mean IGF-1 SDS. Long-term maintenance of IGF-1 SDS in the upper-normal range was associated with lower high-sensitivity C-reactive protein (hs-CRP) levels (median (25–75% range): 0.8 (0.6–1.1) vs. 1.8 (0.8–4.6); p = 0.005). Moreover, a negative correlation was identified between a hs-CRP and the 5-year mean IGF-1 SDS. The association between the upper-normal IGF-1 SDS range and lower body fat percentage lost significance after adjusting for sex, due to the higher proportion of male patients in the upper-normal IGF-1 SDS group. In conclusion, long-term maintenance of upper-normal IGF-1 SDSs was associated with male sex and reduced low-grade inflammation. Randomized controlled studies are needed to evaluate the long-term and sex-specific effects of targeting the upper- vs. lower-normal IGF-1 range in AGHD.</dc:description><dc:date>2025</dc:date><dc:date>2026-02-26 11:00:04</dc:date><dc:type>Neznano</dc:type><dc:identifier>27839</dc:identifier><dc:identifier>UDK: 616.4</dc:identifier><dc:identifier>ISSN pri članku: 1422-0067</dc:identifier><dc:identifier>DOI: 10.3390/ijms26052010</dc:identifier><dc:identifier>COBISS_ID: 227344899</dc:identifier><dc:language>sl</dc:language></metadata>
